RMI

RMI, Researched Medicines Industry New Zealand

The Researched Medicines Industry Association (RMI) has an important role to play in representing its members’ views on Government policy, legislation and other matters open to public consultation. For copies of previous submissions click here

Commerce Select Committee	Patents Bill - July 2009
Health Select Committee	Improving New Zealand’s environment to support innovation through clinical trials - April 2010 Public Health Bill - March 08
Health & Disability Ethics Committees	Draft revised National Application Form for Ethical Approval of a Research Project and Guidelines - Feb 08.
Health Research Council	New Appeals Process for Ethical Review Consultation Document - March 2009
High Cost Medicines Panel	Final submission to the High Cost Medicines Panel - February 2010. Copy of Annex 2 referred to in the submission. Initial submission to the High Cost Medicines Panel - October 2009
Ministry of Economic Development	Acceptance of the Protocol Amending the TRIPS Agreement to Implement the Doha Delcaration on TRIPS and Public Health : Discussion Document - Dec 07 Bioprospecting : Harnessing Benefits for New Zealanders - Oct 07
Ministry of Health	NZ Public Health and Disability Amendment Bill 2010 - Jun 10 Proposed Clinical Trials Guidelines - Nov 09 Proposed Changes to Fees Payable Under the Medicines Regulations 1984 - May 09 Ethics of Intervention Studies - Discussion Document and Draft Ethical Guidelines for Intervention Studies - Jun 08 Review of the Appointment Protocol for the Pharmacological and Therapeutics Advisory Committee - Apr 07 Towards a New Zealand Medicines Strategy Consultation Document - Mar 07 Medsafe's Proposal to Increase Fees Payable under the Medicines Act 1981 and Misuse of Drugs Act 1975. March 2006.
Otago/Southland DHB	Bridging the Gap - a partnership between patients, doctors and DHBs to enhance access to unfunded treatments - Feb 2010
Pharmacy Council of NZ	Consultation on the Proposed Pharmacist Prescriber Scope of Practice - July 2010
PHARMAC	Consumer Participation Discussion Document - Dec 09 Proposal to change the format of Section H - Oct 09 2009/10 Multi-product Tender - Oct 09 Input into Consultation on Revised Funding Application Guidelines - July 2009 Input into the Consumer Advisory Committee Terms of Reference Review - July 2009 Consultation on proposal to re-invest a portion of savings back into pharmacy sector - Jan 09 Consultation on the Draft Voluntary Checklist for Health Consumer Organisations Entering into Health Industry Sponsorship - Oct 08 Review of Guidelines for the Pharmacology and Therapeutics Advisory Committee (PTAC) and its Subcommittees - Jun 08 Response to Proposal for levetiracetam - Jun 08 Alternative Brand Access Proposal - Oct 07 High Cost Medicines Review - Mar 07 Draft Guidelines for Pharmacoeconomic Analysis - Oct 06
Joint Agency Establishment Group (JAEG)	Proposed clinical trial regulatory arrangements under the Australia New Zealand Therapeutics Products Authority Draft Order Packaging Requirements for Therapeutic Products Improving Access to Consumer Medicines Information (CMI) and Product Information (PI) Australia New Zealand Therapeutic Products Regulatory Scheme (Advertising) Rule 2006 Therapeutic Products and Medicines Bill - Submission to Government Administration Select Committee Consultation paper on Product Vigilance in the Australia New Zealand Therapeutics Products Authority Australia New Zealand Therapeutics Products Regulatory Scheme (Administration and Interpreation) Rule 2006. Extracts relating to the scheduling of therapeutic products. Consultation on Microbiological Standards for Medicines in the Australia New Zealand Therapeutic Products Authority (ANZTPA). ANZTPA Regulatory Scheme (Admininistration and Interpretation) Rule 2006 ANZTPA Consultation Paper on Fees and Charges and Submission on Fees and Charges under the Australia New Zealand Theraeputics Products Regulatory Scheme Proposed Grouping Order Draft General Requirements for the Labelling of Medicines Australia New Zealand Therapeutic Products ANZTPA Regulatory Scheme (Medicines) Rule 2006 Guidelines for Transition to the Joint Regulatory Scheme for Class 2 Medicines Child Resistant Packaging of Therapeutic Products Discussion Paper : Workflow Practices within Drug Safety and Evaluation Branch (DSEB) of the TGA . January 2006.
Inland Revenue Department	Business Tax Review Discussion Document

design & website by online designs